Source comparison
Thymosin Alpha-1 Hepatitis Complete Guide 2026 Comparison
Thymosin Alpha-1 Monotherapy T-cell maturation, IL-2 upregulation 18–22% HBeAg seroconversion (HBV); not recommended for HCV monotherapy Subcutaneous injection, 1.6mg twice weekly 24–52 weeks Insufficient as standalone therapy. Requires combination with antivi
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 Monotherapy
- T-cell maturation, IL-2 upregulation
- 18–22% HBeAg seroconversion (HBV); not recommended for HCV monotherapy
- Subcutaneous injection, 1.6mg twice weekly
- 24–52 weeks
- Insufficient as standalone therapy. Requires combination with antiviral agents to achieve clinically meaningful viral suppression
- Tα1 + Nucleoside Analogues (HBV)
- Immune restoration + viral polymerase inhibition
- 38–42% HBeAg seroconversion, 52% ALT normalisation
- Tα1 subcutaneous + daily oral entecavir/tenofovir
- 48–104 weeks
- Gold standard for treatment-naive HBV patients; combination addresses both immune dysfunction and active viral replication
- Tα1 + Pegylated Interferon (HCV)
- Immune modulation + broad antiviral activity
- 51% SVR12 (genotype 1); 44% without Tα1
- Tα1 subcutaneous + weekly pegIFN injection
- 24–48 weeks
- Largely replaced by DAA regimens; still relevant in resource-limited settings or interferon-eligible patients
- Tα1 + Direct-Acting Antivirals (HCV)
- Immune restoration + NS5A/NS5B inhibition
- 89% SVR12 in DAA-experienced patients with cirrhosis
- Tα1 subcutaneous + daily oral DAA combination
- 12–24 weeks
- Emerging protocol for salvage therapy; particularly valuable in patients with resistance-associated substitutions or advanced fibrosis
- Interferon Monotherapy (HBV/HCV)
- Broad antiviral and immunomodulatory effects
- 25% HBeAg seroconversion (HBV); 40–45% SVR (HCV genotype 1)
- Weekly or thrice-weekly subcutaneous injection
- 48 weeks (HBV); 24–48 weeks (HCV)
- High adverse event burden (flu-like symptoms, depression, cytopenia); inferior outcomes compared to Tα1 combination or DAA regimens
- Nucleoside Analogues Monotherapy (HBV)
- Viral DNA polymerase inhibition
- Viral suppression in 85–90%; seroconversion in <10% annually
- Daily oral administration
- Indefinite (lifelong in most cases)
- Effective viral suppression but does not restore immune function. Functional cure rates remain low without adjunct immunotherapy